Trial intelligence / Profile preview

Neoadjuvant PD-1 Inhibitor + Chemo + RT in HR+/HER2- Breast Cancer

NCT06639672Phase 2Not yet recruiting

Start: Nov 2024
Primary completion: May 2026

Overview

Phase 2, randomised, open-label trial in Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative) (4 arms). Primary endpoint: Pathologic Complete Response at 2 years. Planned start Nov 2024; status: not yet recruiting.

Conditions

Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative)

Beyond the preview

Go deeper on NCT06639672.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06639672.